Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Eve vs Rivas Medical Weight Loss

Eve
Graded #189

Higher grade

vs+10.699999999999996
Rivas Medical Weight Loss
Graded #437

Lower grade

The verdict

Eve takes it — 66.3/100 to 55.6/100.

Eve grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eve is a women's-health-focused GLP-1 telehealth platform — distinctive positioning in a largely gender-neutral market — offering both compounded semaglutide and tirzepatide (including an oral sublingual…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEve +10
55
45
Dose & formulationEve +48
88
40
Clinical oversightRivas Medical Weight Loss +2
79
81
Labs & monitoringRivas Medical Weight Loss +1
52
53
FulfillmentEve +2
67
65
Contract termsRivas Medical Weight Loss +14
41
55
Eve · left barRivas Medical Weight Loss · right bar

The numbers

MetricEveRivas Medical Weight Loss
WeighScore66.3/10055.6/100
GradeCC
Scorecard rank#189#437
Semaglutide$195/mo (compounded)Not disclosed
Tirzepatide$195/mo (compounded)Not disclosed
CoverageCoverage not published3 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
Eve

Graded #189 · C

Strengths

  • Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
  • Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
  • LegitScript Certified with a verifiable ID
  • Publishes the FDA compounded-medication disclaimer
  • Oral sublingual semaglutide offered alongside injectable

Where it loses points

  • Full states-served list not disclosed publicly
  • 503A pharmacy partner not named, and 503A vs 503B status not specified
  • Named medical director / clinical leadership not disclosed
  • Corporate legal entity not disclosed
  • Governing law / arbitration venue not stated

Strengths

  • Physician-founded (Paul Rivas MD) with 15 clinics plus telehealth
  • Flat price for any dose; weekly provider visits included in every payment
  • Offers both compounded semaglutide and tirzepatide

Where it loses points

  • Expensive: about $498/mo for semaglutide and $715/mo for tirzepatide (billed weekly)
  • Only available in Maryland, Virginia, and Florida
  • Weekly-visit concierge model requires more frequent engagement than mail-order

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard